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The high-density-lipoprotein-(HDL-) associated esterase paraoxonase 1 (PON1) is a likely contributor to the antioxidant and
antiatherosclerotic capabilities of HDL. Two nonsynonymous mutations in the structural gene, PON1, have been associated
with variation in activity levels, but substantial interindividual diﬀerences remain unexplained and are greatest for substrates
other than the eponymous paraoxon. PON1 activity levels were measured for three substrates—organophosphate paraoxon,
arylester phenyl acetate, and lactone dihydrocoumarin—in 767 Mexican American individuals from San Antonio, Texas. Genetic
inﬂuences on activity levels for each substrate were evaluated by association with approximately one million single nucleotide
polymorphism (SNPs) while conditioning on PON1 genotypes. Signiﬁcant associations were detected at ﬁve loci including regions
on chromosomes 4 and 17 known to be associated with atherosclerosis and lipoprotein regulation and loci on chromosome 3
that regulate ubiquitous transcription factors. These loci explain 7.8% of variation in PON1 activity with lactone as a substrate,
5.6% with the arylester, and 3.0% with paraoxon. In light of the potential importance of PON1 in preventing cardiovascular
disease/events, these novel loci merit further investigation.
1.Introduction
More than 2,200 Americans die from cardiovascular disease
each day with 75% of those deaths attributable to ather-
osclerosis [1]. Atherosclerosis is characterized by the buildup
of fatty lesions, inﬂammation, and scarring of arterial walls
with oxidative stress as a primary contributing factor. Para-
oxonase 1 (PON1) is a high-density-lipoprotein-(HDL-) as-
sociated esterase which appears to contribute to the antiox-
idant and antiatherosclerotic capabilities of HDL. PON1 is
synthesized in the liver and secreted into the bloodstream
where it is capable of breaking down both man-made and
naturally occurring compounds. Named for its ability to
hydrolyze organophosphates like paraoxon [2, 3] found in
insecticides, PON1 is also able to hydrolyze N-acyl-homo-
serine, a lactone used by pathogenic bacteria [4], and lipid
peroxides, thereby inhibiting the formation of foam cells
known to contribute to atherosclerosis [5, 6].
PON1 has been widely studied following evidence that
high activity levels decrease systemic oxidative stress and are
associated with a lower incidence of cardiovascular events
[7]. PON1 levels have been tied to a number of other dis-
orders including type 1 and 2 diabetes [8, 9], thyroid dys-
function [10], uremia [11], renal failure [12], and inﬂamma-
tory response [13].
ThestructuralgenePON1isbyfarthelargestcontributor
to variation in serum PON1 activity levels with four known
single nucleotide polymorphisms (SNPs) in the promoter
region [14–16] and two nonsynonymous substitutions in the
coding region of the gene [17, 18] shown to signiﬁcantly in-
ﬂuence activity levels. Amino acid substitution 192Q>R
(rs662) speciﬁes 2 allozymes [17] whose diﬀerences in acti-
vity are substrate dependent. The R allozyme shows great-
er activity for the organophosphates paraoxon and feni-
troxon while the Q form more eﬃciently hydrolyzes other
organophosphates including diazoxon, soman, and sarin.2 Journal of Lipids
Phenyl acetate is hydrolyzed at the same rate by both forms.
[19–21] The 192Q>R substitution is associated with up
to 13-fold interindividual diﬀerences in PON1 activity [22]
and an adjusted hazard ratio for major cardiac events of
1.5 [23]. The 55L>M (rs854560) substitution has also been
associated with variation in serum PON1 activity levels, but
has a smaller eﬀect size. These polymorphisms have also
been linked to Parkinson’s disease [24], inﬂammatory bowel
diseases [25], and, controversially, to Alzheimer’s disease and
vascular dementia [26].
PON1 is part of a family of genes including PON2 and
PON3 located within a 140kb region at 7q21.3. Although
PON2 and PON3 also synthesize paraoxonase proteins,
PON2 is not excreted into the blood and any eﬀect by ei-
ther protein on atherosclerosis or cardiovascular disease is
small [27]. Although the PON region explains a large de-
gree of the variation in PON1 activity, PON1 activity levels
are still better predictors of disease than PON1 genotypes
alone [22, 28]. This supports the existence of additional, un-
identiﬁed polymorphisms associated with PON1 activity as
well as potential epigenetic contributors.
Despite the large body of literature on the PON loci,
this study is the ﬁrst to take a genome-wide association ap-
proach to identify additional genomic regions contributing
to interindividual variation in PON1 activity. Previous
studiesofthissampleidentiﬁedQTLsforPON1activitywith
paraoxon as a substrate on chromosomes 7 (PON1), 12, 17,
and19usingwhole-genomemultipointlinkageanalysis[29].
Further investigation, which included alternate substrates
and conditioned on the major QTL at chromosome 7, locat-
ed additional QTLs on chromosomes 1, 3, and 14 [30].
2. Methods
2.1. Subjects. Samples were drawn from the San Anto-
nio Family Heart Study (SAFHS) which is composed of
1414 individuals (837 females, 577 males) belonging to
42 extended pedigrees originating with probands randomly
ascertained with respect to disease status and phenotype. All
probands were Mexican-American individuals between the
ages of 40 and 60 at the time of ascertainment, living in
San Antonio, TX, with a minimum of six oﬀspring and/or
siblings who were at least sixteen years of age and also
living in the area. After giving their informed consent, par-
ticipants underwent a physical examination, demographic
and lifestyle interview, and provided blood samples for
genotypingandbloodchemistryanalysis.Thestudyprotocol
was approved by the Institutional Review Board at the
UniversityofTexasHealthScienceCenterinSanAntonioand
is described in more detail in a previous publication [31].
2.2. Paraoxonase Activity. Based on previous evidence of
genetic variation giving rise to diﬀerent activity levels in
a substrate-dependent fashion, PON1 activity was assessed
on an organophosphate, an arylester, and a lactone. Activ-
ity was calculated for 767 individuals based on standard
spectrophotometric assays described previously [32]. Brieﬂy,
PON1-para activity was determined from the rate of con-
version of paraoxon to p-nitrophenol, PON1-aryl activity
was calculated from the conversion of phenyl acetate to
phenol, and PON1-lact activity was based on the conversion
of dihydrocoumarin to 3-(2-hydroxyphenyl)propionate. The
underlying shared genetic relationship between the activity
levels was estimated by calculating the shared genetic covari-
ance (ρG) for each pair of activity levels. PON-aryl showed
signiﬁcant evidence of a shared genetic contribution with
both PON-lact (ρG = 0.54, P = 1.9e − 19) and PON-para
(ρG = 0.65, P = 5.5e − 23); however, the genetic correla-
tion between the activity levels for PON-lact and PON-para
was essentially zero. This suggests that there are likely to
be independent variants inﬂuencing activity levels for the
diﬀerent substrates.
2.3. Statistical Genetic Analyses. DNA was extracted from
buﬀy coats and used for genotyping on a series of Illumina
microarrays (Illumia, Inc., San Diego, CA). 931,219 SNPs
passed quality control and were included in the genome-
wide association (GWA) analysis. Where it could be done
with a high degree of certainty, known pedigree relationships
were used to infer missing genotype data using the PEDSYS
routine INFER [33]. For ambiguous genotypes, a weighted
average of the possible genotypes was used.
Association was assessed for each measurement of para-
oxonase activity using the measured genotype test imple-
mented in the program SOLAR(Sequential Oligogenic Link-
age Analysis Routines) [34] which takes into account rela-
tionships among family members. For all analyses, paraox-
onase activity and age were normalized and sex, age, age2,
and the interaction of sex by age were used as covari-
ates. Additional covariates considered but not found to be
associated with PON1 activity in this sample (P>0.1)
include dietary measures (proportion of saturated fats, mo-
nounsaturated fats, polyunsaturated fats, and fat calories
reported in diet), alcohol and cigarette consumption, body
mass index (BMI), and total metabolic equivalents as a
measure of activity level. To minimize the risk of false asso-
ciations due to stratiﬁcation in this admixed sample, prin-
cipal component analysis was performed on the full set of
approximately one million genotypes to capture the total
genetic variation in the sample and the ﬁrst four principal
components (accounting for only 2.8% of the variation in
the sample) were included as covariates. The eﬃcacy of this
correction for stratiﬁcation was examined by calculating λ
from the distribution of the lower 90% of P values for each
GWA. There was no evidence of overdistribution due to
stratiﬁcation as all λ values were less than 1.02. Manhattan
andQ-QplotsforeachGWAcanbefoundinSupplementary
File 1 available online at doi:10.1155/2012/189681.
To identify genes contributing to the residual variation,
genome-wide association was assessed while including geno-
typesatthetwomajorPON1substitutions192QRand55LM
(rs662 and rs854560) as covariates. Despite the inclusion
of these known variants, other SNPs in the PON region
of chromosome 7 still showed association with PON1 acti-
vity for all three substrates. This suggests that additional
variation in PON1 or nearby genes is contributing to theJournal of Lipids 3
variation in PON1 activity levels. To remove all eﬀects of
the PON loci, four additional SNPs—rs854522, rs854534,
rs757158, and rs7803148—each tagging a haploblock in the
region surrounding the three PON genes—were included as
covariates for the GWA analysis. With the inclusion of these
covariates, there is 95% power to detect variants with an
eﬀect size (RG
2) of at least 0.041 for PON1-aryl, 0.041 for
PON1-lact, and 0.024 for PON1-para.
2.4. Candidate Gene Identiﬁcation. The program SUSPECTS
was used to identify candidate genes in the region surround-
ing each SNP showing signiﬁcant association with PON1
activity [35]. SUSPECTS determined candidate genes on the
basis of similarities in structure, gene ontology, InterPro
domains, and/or gene expression with genes known to be
related to atherosclerosis, cholesterol regulation, or heart
disease.Additionally,allgeneswithin250kboftheassociated
SNP were investigated for potential functional relationships
to PON1 activity. A 250kb region is suﬃcient to encompass
more than 97% of haploblocks in Mexican populations [36].
TofurthercontextualizetheresultsoftheGWAanalysis,gene
set and pathway enrichment analysis was performed using
the Database for Annotation, Visualization, and Integrated
Discovery (DAVID) [37, 38]. All markers were annotated
and the genes found in the top 1% of associations were
clustered based on similarity of gene ontology (GO) terms
and compared to the genes represented by the remaining
99% of markers.
Additionally, the relationship between gene expression
levels measured on an Illumina Sentrix Human Whole
Genome(WG-6)SeriesIBeadChip array[39]andassociated
SNPs was calculated from the genetic covariance in a
polygenic model including sex, age, age2,s e x ∗age, 192QR,
55LM, and the additional associated loci in the PON region.
3. Results
The heritability of paraoxonase activity varies with substrate,
h2 = 0.65 for phenyl acetate (PON1-aryl), h2 = 0.73 for
paraoxon (PON1-para), and h2 = 0.79 for dihydrocoumarin
(PON1-lact) after the inclusion of sex and age in the
model. Similarly, the phenotypic variation explained by the
covariates and the PON1 alleles diﬀers among the substrates
(Table 1). Cumulatively, age, sex, and their interaction eﬀect
explain less than 4% of the variation in PON1 activity
for all substrates. In this sample, known PON1 variants
(192QR and 55LM) explain 50.4% of the variation in PON1-
para activity but only 9.6% of the variation in PON1-
aryl and 12.4% of the variation in PON1-lact activities.
Previous research in individuals of Korean ancestry reported
that 192QR explained 65.8% of variation in PON1-para
activity [40]. A similar study in individuals of European
ancestry estimates that 192QR explained 46% and 55LM
explained 16% of the PON1-para variation [41]. Although
the haplotype blocks in the Mexican American sample are
similar in location to those seen in the CEPH Europeans
downloaded from HapMap, the linkage disequilibrium (LD)
is more extreme, likely due to admixture. This increase in
Table 1: Proportion of variance explained by covariates. The pro-
portion of variation explained by each signiﬁcant variable was cal-
culated for the three substrates by adding each to a polygenic model
in SOLAR.
Variation explained
Covariate PON1-aryl PON1-lact PON1-para
Sex 0.4% 0.0% 0.4%
Age 1.1% 1.4% 0.4%
Age2 1.1% 1.9% 0.1%
Sex∗age 0.7% 0.4% 0.7%
192QR 3.9% 8.3% 36.5%
55LM 5.7% 4.1% 13.9%
rs854522 2.7% 1.8% 1.1%
rs854534 3.4% 3.8% 2.1%
rs757158 11.5% 9.2% 4.1%
rs7803148 0.9% 1.1% 0.6%
LD would be expected to inﬂate the explanatory power of
the known polymorphisms, so it is unclear why 192QR and
55LM explain less variation in this sample.
To assess the residual variation in the PON region of
chromosome 7, haplotype blocks were identiﬁed using the
solid spine of linkage disequilibrium method implemented
in Haploview [42]. The SNP rs757158 tags a haploblock
including the 5  promoter region of PON1 and explains the
greatest proportion of remaining variation in PON1 activity
for all substrates. This is in line with previous reports of
promoter polymorphisms. As seen for 192QR and 55LM, the
promoter polymorphisms have diﬀerent eﬀects depending
on the substrate—this region explains a larger proportion of
the variation in PON1-aryl and PON1-lact than in PON1-
para. Polymorphisms in the remaining haploblocks are also
associated with variation in PON1 activity. rs854534 tags a
haplotype block including the majority of the genic region
of PON1, rs854522 tags a region downstream of all the PON
genes, and rs7803148 lies in the genic region of PON2 and
tags a haplotype block that includes the entirety of that
gene and the majority of PON3. Variation in these three
haploblocks cumulatively explains less variation in PON1
activity than the haploblock tagged by rs757158. Following
the inclusion of these markers as covariates, there are no
signiﬁcant associations in the PON regions for PON1-para
or PON1-lact; however, PON1-aryl activity is suggestively
associated with rs2299262, an intronic SNP in PON1 that
explains 2.8% of the variation in PON1-aryl activity. It
should be noted that while the proportion of variation
described here and subsequently is useful for comparing
the relative contributions of the loci to the variation in
activity levels, there can be a substantial upward bias in these
estimates unless replicated in an independent sample [43].
The variation in eﬀect size of the polymorphism by
substrate bolsters the previously identiﬁed substrate-speciﬁc
eﬀect and indicates additional genetic variants must be
contributing to diﬀerences in activity levels for PON1-aryl
and PON1-lact in particular. The relatively large amount
of variation captured by including additional SNPs in the4 Journal of Lipids
Table 2: Summary of Signiﬁcant and Suggestive Associations. SNP associations varied among substrates with overlap only at rs1078701
on chromosome 4. For each SNP, the chromosomal location, proportion of variation in PON1 activity explained, measured genotype test
P-value, and minor allele frequency are listed. Shoulder SNPs are SNPs ranking in the top 5% of associations located within 500kb of the
signiﬁcantly associated SNP. Genes identiﬁed by SUSPECTS are within 7.5Mb of the candidate SNP and have a similarity score greater
than 15. Bolded genes are discussed in the texts as the most likely contributors to PON1 activity based on known function, however, other
genes may have unknown functions important in the regulation of PON1. The two associated SNPs on chromosome 3 are in perfect linkage
disequilibrium and explain 2.7% of the variation in PON1-lact cumulatively.
Substrate SNP Chr Position Variation
Explained MG p MAF Shoulder
SNPs SUSPECTS Genes
para rs12083993 1 64,691,396 1.2% 1.8E −07 0.3% 34
ALG6, ANGPTL3,
CYP2J2, IL12RB2,
INSL5, LEPROT,O M A 1 ,
PTGER3
lact rs13322362 3 76,613,497 2.7% 4.8E −07 5.4% 6 PROK2, ROBO1,
ROBO2 lact rs11915977 3 76,613,530 4.8E −07 5.5%
para 1.8% 4.7E −09 32
aryl rs1078701 4 8,241,119 2.8% 3.0E −08 2.2% 19
ADD1,C P Z ,D G K Q ,
FGFBP1, FGFR3,
FGFRL1, HGFAC,
HS3ST1, LRPAP1,
MXD4
lact 2.3% 3.8E −07 15
aryl rs2299262 7 94,787,864 2.8% 1.3E −07 43.9% 24 PON1
lact rs7225624 17 47,811,373 2.9% 4.7E −09 0.3% 4
ABCD4, ADAM11,
DGKE, GRN, HOXB2,
NGFR, NMT1, OSBPL7,
PLCD3, PCTP, SCPEP1,
SLC35B1
region once the known PON1 variants are included in the
modelsuggestsﬁner-scaleanalysisofthisregionmayidentify
additional contributing polymorphisms.
Association was assessed for each SNP using a genome-
widesigniﬁcancethresholdofP<5E−8withP<5E−7con-
sidered a suggestive association. As this study assesses asso-
ciations in Mexican-American families, it should be noted
that there is wider linkage disequilibrium than would be
found in a population of randomly mating, unadmixed indi-
viduals, making this value of α conservative. Using these
thresholds,twoSNPsareassociatedwithPON1-paraactivity,
four with PON1-lact activity (two of which are in perfect
LD), and two with PON1-aryl activity after conditioning
on the associated SNPs in the PON region (Table 2,S u p -
plemental File 1). Only a single SNP (rs1078701) on chro-
mosome 4 is signiﬁcantly associated with activity on all two
substrates and suggestively associated for the third. The pro-
portion of variation explained by rs1078701 varies among
the diﬀerent substrates, ranging from 1.8–2.8%.
Located less than 200kb from rs1078701, ACOX3 is a
strong positional candidate gene as well as a potential con-
tributor to cholesterol regulation. This gene encodes a per-
oxisomal pristanoyl-CoA oxidase essential for the catabolism
of branched fatty acids into precursors for cholesterol bio-
synthesis [44]. However, the degree to which peroxisomal
fatty acid metabolism contributes to circulating cholesterol
is unclear [45]. Also found near rs1078701 is LRPAP1 which
produces a glycoprotein that has been linked with gallstone
disease caused by an excess of cholesterol [46]a n dw i t h
cholesterol-relatedbraindisorderssuchasdementia[47]and
Alzheimer’s disease [48]. LRPAP1 regulates the amount of
LDL-receptor-relatedproteinexpressedintheliverandbrain
and may also act as a chaperone for lipoprotein lipase [49]. A
ﬁnal candidate gene from this region, ADD1,i sl o c a l i z e dt o
the erythrocyte membrane and is involved in renal sodium
handling and hypertension [50]. It has been implicated in
blood pressure, adipogenesis, and coronary heart disease
[51, 52]. The other signiﬁcantly associated SNP is rs7225624
on chromosome 17 which explains 2.9% of the observed
variationinPON1-lact.PCTP is6Mbpawayfromrs7225624,
buthasastrongSUSPECTSscoreduetheinvolvementofthis
gene in cholesterol metabolism and transport as well as lipid
binding. PCTP is a transfer protein found in macrophages,
which are pervasive in atherosclerotic legions, and work in
model organisms indicates PCTP regulates lipid eﬄux into
the blood stream [53, 54].
Two additional loci show suggestive associations with
PON1 activity. Located on chromosome 1, rs12083993 is
associated with variation in PON1-para and replicates a
previous linkage result for PON1-aryl [32]. This polymor-
phism explains 1.2% of the variation in PON1-para and
SUSPECTSprioritizesthreecandidategenesinvolvedinlipid
metabolism. ANGPTL3 is predominantly expressed in the
liver, but suppresses lipoprotein lipase in the blood stream
which in turn hydrolyzes HDL [55]. Polymorphisms in this
gene are also associated with increased arterial wall thicknessJournal of Lipids 5
[56]. LEPROT is involved in the cell-surface expression of
the leptin receptor, regulation of growth hormones linked to
obesity in mice, and cell signaling in response to circulating
nutrient levels [57, 58]. Finally, CYP2J2 is a member of
the cytochrome P450 gene family which is widely involved
in the oxidation of organic substances and metabolism.
CYP2J2 is primarily expressed in the aorta and coronary
artery and has been linked to hypertension risk [59, 60].
The most likely mechanism for this relationship is the meta-
bolism of arachidonic acids to epoxyeicosatrienoic acids
(EETs) which are vasodilating agents capable of inhibiting
inﬂammatory response and promoting ﬁbrinolysis [61, 62].
Because PON1 can be inactivated under oxidative conditions
[63] similar to those present in the absence of functional
CYP2J2 [64, 65], this association may be related to the rea-
lized activity of inactivated PON1 enzyme rather than the
basal concentration of PON1 or the activity level under nor-
mal plasma conditions.
A suggestive association was also found for PON1-lact
with two SNPs in perfect LD (rs13322362 and rs11915977)
on chromosome 3. Jointly, these explain 2.7% of the overall
variation in PON1-lact. Although a region of chromosome
3 was identiﬁed in previous linkage analyses [32], that QTL
is more than 44 Mbp from rs13322362. This region of the
genome contains few genes but may contain one or more
transcription factors indicated by the signiﬁcant association
between rs13322362 and transcript levels of three genes in-
cluding SLC25A26, a mitochondrial transport gene [66],
PROK2,whichregulatescircadianrhythms[67],andRYBP,a
broadly expressed binding protein essential for development
[68].
The candidate genes identiﬁed in this analysis are con-
sistent with the evidence of enrichment of the top 1% of
associations for genes analyzed in DAVID. These results
suggest the involvement of pathways related to vasculature
development and angiogenesis, cell junctions and signaling,
cell adhesion, transmembrane glycoproteins and ion trans-
port, and immunoglobulin.
4. Discussion
The use of known polymorphisms in PON1 as covariates
in this genome-wide association analysis is an unusual but
essential method for identifying regions of the genome with
smaller eﬀects. By accounting for more than 40% of the
variation in PON1 activity in this way, four additional re-
gions of the genome showing an association with residual
PON1 activity were identiﬁed that could not otherwise be
isolated.
The pathways through which candidate genes inﬂuence
PON1activityare,formanyofthegenes,unclear.Frequently,
this is due to a lack of full, functional understanding of
the genes themselves. Genes that are associated with choles-
terol levels and associated syndromes, but have no clear
mechanism, may be contributing to the PON1 pathway but
further research would be required to demonstrate this. Be-
cause PON1 binds to, and is carried by, nonoxidized HDL
molecules, these regions may play a role in plasma HDL
concentration which would indirectly increase PON1 con-
centrationandactivity.Additionally,itisimportanttorecog-
nize that PON activity is likely inﬂuenced by the tertiary
structure of the PON1 protein itself or the circulating levels
of PON in the blood, which may be inﬂuenced by the lipo-
protein milieu.
It is necessary, therefore, to consider these results within
the broader network of genes and proteins involved in the
regulationoflipidmetabolisminthebloodstream.However,
lipid metabolic pathways are not the only ones implicated
in these association results. Ubiquitous transcription factors
and genes related to oxidative stress were also identiﬁed
and could play substantial roles in the regulation of PON1
concentration in the blood or the inactivation of PON1
which would decrease activity even in the presence of high
levels of the enzyme. Considering the number of factors
associated with the activity of single enzyme, future work
on the genetic underpinnings and biochemical regulation of
atherosclerosis, hypertension, cholesterolemia, and inﬂam-
matory diseases more broadly must be understood in the
broadest biochemical context.
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